Open AccessNon-small cell lung cancer in elderly – retrospective study comparing single-agent versus doublet chemotherapy
Author(s) -
Élia Cipriano,
Helena Magalhães,
F. Estevinho
Publication year - 2020
Publication title -
revista do grupo de estudos do cancro do pulmão
Language(s) - English
Resource type - Journals
eISSN - 2184-8084
pISSN - 1645-9466
DOI - 10.32932/gecp.2020.12.009
Subject(s) - medicine , lung cancer , chemotherapy , retrospective cohort study , clinical endpoint , oncology , population , clinical trial , environmental health
Background: In non -small cell lung cancer (NSCLC) elderly patients with advanced disease and without driver mutations, questions remain if they benefit from doublet chemotherapy (ChT) or single -agent ChT. Methods: A retrospective study characterizing elderly NSCLC patients with advanced disease. The primary endpoint was overall survival (OS) after doublet ChT and single -agent ChT, calculated using Kaplan -Meier method and Log Rank test. Results: Forty -six patients with locally advanced or metastatic disease were treated with ChT (22 with platinum- -based doublet ChT and 24 with single -agent ChT). With a median follow -up of 26.6 months (mo.), the median OS was 8.4 mo. in doublet ChT and 7.0 mo. in single‑agent ChT, p=0.441. Conclusions: There were no statistically significant differences in survival between platinum -based doublet and monotherapy ChT in our studied population.